scholarly journals THE EXPERIENCE OF DENERVATION OF FACET JOINTS IN THE LUMBAR SPINE

2019 ◽  
Vol 16 (1) ◽  
pp. 57-62 ◽  
Author(s):  
M. V. Shpagin ◽  
A. V. Yarikov ◽  
I. A. Nazmeev ◽  
S. A. Gorelov ◽  
A. P. Fraerman

Objective.To analyze the immediate and long-term results of denervation of facet joints for facet syndrome in the lumbar spine.Material and Methods.The immediate and long-term results of the treatment of 59 patients with severe pain in the lumbar spine who underwent facet joints denervation were studied.Results.On a MacNab scale, 39 (66.1 %) patients rated the treatment results as good, and 20 (33.9 %) as mediocre. According to the Nurick scale, the 2nd level results of treatment (improvement) were recorded in 55 (93.2 %) cases, the 3rd level ones (unaltered) – in 4 (6.8 %). The follow-up data were collected on 37 (62.7 %) patients from 1.7 months up to 1.5 years after surgery: 13 (35.2 %) of them rated the long-term treatment results as good, 8 (21.6 %) – as mediocre, and 16 (43.2 %) – as bad.Conclusions.Denervation of facet joints is an effective minimally invasive method for treating facet syndrome caused by spondyloarthrosis. It allows significantly reducing pain and improving the quality of life of patients in the early and long-term postoperative period.

Author(s):  
Anton Yarikov ◽  
Maxim Shpagin ◽  
Iliya Nazmeev ◽  
Sergey Gorelov ◽  
Olga Perlmutter

The immediate and long-term results of treatment of 30 patients with severe pain syndrome of the lumbar region, who underwent operations on denervation of DOS, were studied. The aim of the study was to evaluate the effectiveness of minimally invasive technologies for the treatment of pain in the lumbar region (denervation of DOS), to study the near and distant results of these treatment methods. Denervation DOS is an effective minimally invasive method for the treatment of facet syndrome caused by spondylarthrosis. It allows in the early and distant postoperative periods to significantly reduce the pain syndrome and improve the quality of life of patients.


Author(s):  
Khromov A.A. ◽  
Gumanenko E.K. ◽  
Linnik S.A.

Severe combined injuries, and especially polytrauma, differ significantly from other types of injuries by high requirements for the organization of medical care at all its stages, miltidisciplinarity, high financial costs, poor short-term outcomes and long-term treatment results. Therefore, the search for new concepts, strategies and tactics for the treatment of victims is an urgent problem not only for surgeons, resuscitators and traumatologists, but also for healthcare in general. Fractures of long tubular bones accompanying severe combined injuries or polytrauma pose a lesser threat to the life of the victim than severe traumatic brain injuries or damage to internal organs, but they are the main cause of long-term treatment and disability. Such victims make up a significant group of patients-66.2%, therefore they represent a separate problem in traumatology and injury surgery. A modern solution to this problem, improving the results of treatment and the quality of life of victims after suffering a severe combined injury or polytrauma is possible on the basis of new approaches, as well as on the new ideology of osteosynthesis. In the present study, 392 minimally invasive osteosyntheses were performed in 274 patients with severe combined trauma and polytrauma. The indication was the need to fix fractures in order to create favorable conditions for rapid and lasting fusion, early functional treatment and rehabilitation of victims, and to achieve the highest possible level of quality of life after treatment. The possibility and duration of osteosynthesis were determined by the severity of the condition of the victims, assessed by objective methods: a simple clinical scale of VPH-SG or, much less often, specialized resuscitation scales of VPH-SS, SAPS or MODS. The surgical intervention was possible when the severity of the victim's condition reached the highest level of compensation: 16-30 points on the VPH-SG scale. The immediate outcomes of treatment of 274 patients with severe combined trauma and polytrauma after performing a full and final volume of surgery were good. There were no fatal outcomes. The frequency of mild local infectious complications in the field of surgical intervention was 4.0%. The average duration of inpatient treatment was 23.8±2.3 days: with closed intramedullary osteosynthesis - 19.8±0.3 days, with bone osteosynthesis - 24.2±1.2 days, with non - focal osteosynthesis-27.3±1.9 days. The long-term and anatomical and functional results of treatment were analyzed in 158 patients. There were no unsatisfactory long-term results of treatment. Good long-term results were achieved in 81.0%, satisfactory – in 19.0% of the victims. Thus, the results of the analysis of the immediate outcomes and long-term results of treatment of fractures of long tubular bones using the technology of minimally invasive osteosynthesis in patients with severe combined trauma and polytrauma demonstrated the high effectiveness of this surgical technology, on the one hand, and the direct dependence of the treatment outcomes on the severity of the injuries, the severity of the condition of the victims and the number of fractures in one victim, on the other hand.


Author(s):  
Anatoly A. Bakaev ◽  
Alexander V. Kovtunenko ◽  
Sergey N. Tymchuk

Maxillary sinus cancer is one of the most complex malignancies to treat and has an unfavorable prognosis for long-term outcomes. The purpose of the study: based on the evaluation of long-term treatment outcomes (mortality, survival) to analyze the effectiveness of treatment of patients with maxillary sinus cancer and other factors which influence the outcome, including the level of expression of molecular markers. Object and methods: Long-term results of surgical treatment of 103 patients with maxillary sinus cancer stage II-IV (T2-4N0-3M0) were evaluated, which was performed in the ENT oncology department of І.І. Mechnikov Dnipropetrovsk Regional Clinical Hospital over the period of 2011-2017. Remote follow-up of patients was conducted until 2019. Results: The effectiveness of the treatment is confirmed by the analysis of survival in the studied sample: annual survival of 87.36% (95% CI 80.94-93.78); three-years’ survival – 42.75% (95% CI 33.2-52.3); five-years’ survival – 19.76% (95% CI 12.07-27.45); median survival – 32.13 (95% CI 27.0-53.0) months. Using a regression analysis of the proportional risks by Cox, it was proved that patients with recurrences of thyroid cancer die from cancer 3.13 times more often (p=0.009) than individuals in whom cancer was not accompanied by recurrence, with increasing expression of the marker TIMP-1 per unit the risk of adverse outcomes for patients is reduced by 2.56 times (p=0.034). Conclusions: Evaluation of long-term treatment outcomes (mortality, one-, three-, and five-years’ survival) of patients with maxillary sinus cancer has proven the effectiveness of treatment and approaches to their determination.


2019 ◽  
Vol 5 (12) ◽  
pp. 156-162
Author(s):  
M. Sabyraliev

Surgical treatment of patients with spinal injuries, accompanied by traumatic stenosis of the spinal canal, is an urgent and discussed problem of modern vertebrology. Surgical treatment of 111 patients with various injuries of the thoracolumbar spine was performed. In 40 patients, post-traumatic stenosis was eliminated using ligamentotaxis using transpedicular osteosynthesis. The immediate results of treatment were followed up in all patients: good results were obtained in 33 (82.5%) cases; satisfactory — in 6 (15.0%), unsatisfactory — in 1 (2.5%). Long-term results with a follow-up of more than 1 year were followed up in 27 (67.5%) patients; good results were obtained in 20 (74.0%), satisfactory in 7 (25.0%).


2003 ◽  
Vol 112 (3) ◽  
pp. 276-279 ◽  
Author(s):  
Bassem Said ◽  
Marshall Strome

To assess the long-term efficacy and morbidity of radiofrequency volumetric tissue reduction (RFVTR) of the soft palate for snoring, we examined the medical records of 39 patients who received this treatment at an academic medical center. Telephone interviews were conducted with the patients to evaluate the long-term subjective efficacy and sequelae. The average follow-up was 14 months (range, 3 to 26 months). Twenty-eight patients (72%) responded to treatment, defined as a 4-point decrease on a 10-point scale. The self-reported snoring score decreased an average of 52% (8.8 ± 1.9 to 4.2 ± 2.9). Sixty-seven percent of the patients were satisfied. The response to treatment did not always correlate with patient satisfaction. The snoring relapse rate was 11% among responders. No significant differences were identified between responders and nonresponders. No significant complications or long-term sequelae were observed. We conclude that RFVTR of the palate is a relatively safe and effective long-term treatment for snoring. Defining realistic pretreatment expectations is important in maximizing patient satisfaction.


2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 290-290 ◽  
Author(s):  
Daniel Peter Petrylak ◽  
Thomas Powles ◽  
Joaquim Bellmunt ◽  
Fadi S. Braiteh ◽  
Yohann Loriot ◽  
...  

290 Background: Atezo (anti–PD-L1) has demonstrated safety and efficacy in a broad range of cancers and is approved in the United States for mUC previously treated with platinum-based chemotherapy. Here we report long-term results in mUC from Phase Ia study NCT01375842 (PCD4989g). Methods: Previously treated mUC patients received atezo 15 mg/kg or 1200 mg IV q3w. Enrollment in this Phase Ia expansion cohort initially required PD-L1–selected status and later opened to patients regardless of PD-L1 expression on tumor-infiltrating immune cells. The primary endpoint was safety/tolerability. Secondary endpoints included investigator-assessed RECIST v1.1 ORR (confirmed), DOR and OS. Results: 95 patients were safety evaluable (Table). Median age was 66 years, 76% were male and 80% had primary bladder tumors. 61% had ECOG PS 1. 52% received ≥ 3 prior systemic therapies for mUC (70% platinum). Median treatment duration was 3 months (range: 0-32 months); 24% were treated for ≥ 1 year. Treatment-related AEs occurred in 66% (all Grade) and 8% (Grade 3-4) of patients. No treatment-related deaths were reported. In 94 objective response–evaluable patients (follow-up ≥ 12 weeks), the ORR was 27% (95% CI: 18, 37%), and the CR rate was 10%; the SD rate was 19%. mDOR was 22.1 months (95% CI: 12.1, NE months) in all patients; 56% of responses (7/9 CRs and 7/16 PRs) were ongoing at the December 15, 2015 data cutoff. With a 24-month median follow-up duration (range: 1+ to 32 months), the 1-year OS rate was 47% (95% CI: 36, 58%), and the 2-year rate was 29% (19, 40%); mOS is in the Table. Updated clinical data with further follow-up and analyses by PD-L1 status will be presented. Conclusions: Long-term treatment with atezo was well tolerated, without new safety signals in heavily pre-treated mUC patients. The durability of responses, including CRs, along with extended OS, confirm atezo as a new standard for previously treated mUC patients. Clinical trial information: NCT01375842. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document